STOP PRESS: GCI Healthcare to promote arthritis drug

Wyeth Laboratories has hired GCI Healthcare to promote a new treatment for rheumatoid arthritis called Enbrel. Fees are expected to top pounds 100,000 for the trade account which was won following a four-way pitch two weeks ago. Rheumatoid arthritis is a severe inflammatory condition which affects up to 1.5 per cent of the UK population. The agency will target health professionals through seminars and specialist media.

Wyeth Laboratories has hired GCI Healthcare to promote a new

treatment for rheumatoid arthritis called Enbrel. Fees are expected to

top pounds 100,000 for the trade account which was won following a

four-way pitch two weeks ago. Rheumatoid arthritis is a severe

inflammatory condition which affects up to 1.5 per cent of the UK

population. The agency will target health professionals through seminars

and specialist media.



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.